Russia’s first COVID-19 vaccine ‘Avifavir’ and all related information.

Unknown Emirati helps stranded Ghanaians
Unknown Emirati helps 200 stranded Ghanaians.
June 2, 2020
Coutinho likely to return to an English club. Bayern has plans.
Coutinho likely to return to an English club – Sources said.
June 2, 2020

Russia’s first COVID-19 vaccine ‘Avifavir’ and all related information.

Russia's first COVID-19 vaccine 'Avifavir' and all related information.

Image Source: Gulf News

Russia’s first COVID-19 vaccine ‘Avifavir’ and all related information. Fast-track approval of flu drug comes amidst claims of shorter recovery time for patients.

Scientists around the world had been hard at work to find antivirals specific to SARS-CoV-2, the virus that causes COVID-19.

Several drugs — such as chloroquine, arbidol, and remdesivir, and various other drug combinations — have undergone clinical studies to test their efficacy and safety in combating the coronavirus.

Avifavir is an anti-influenza medication in Japan approved in 2014.

It has been repurposed to fight COVID-19. Preliminary trials are said to have shown that Avifavir could shorten recovery times for patients with the coronavirus.

On May 30, 2020 (Saturday) Russia’s Ministry of Health approved Avifavir for emergency use to treat COVID-19, after “encouraging” results from clinical trials of the generic version (Favipiravir) in several countries, including China and Japan. It is Russia’s first COVID-19 drug.

Trials had been done around the world — including China, Japan, South Korea, Europe, the US, and India.

Now, Russia has licensed the antiviral drug Avifavir against coronavirus. Russian health authorities have given a green light to a clinical trials.

Favipiravir works by blocking the ability of a virus to replicate inside a cell. Some doctors began trying Favipiravir to treat coronavirus patients early on, reasoning that its anti-viral properties would be applicable.

Read more on Gulf News

News Source: Gulf News

Leave a Reply

Your email address will not be published. Required fields are marked *